Results 341 to 350 of about 9,453,577 (435)

Polygenic scores for disease risk are not associated with clinical outcomes in Parkinson’s disease

open access: yes
Tan MM   +22 more
europepmc   +1 more source

Targeting signaling pathways in neurodegenerative diseases: Quercetin's cellular and molecular mechanisms for neuroprotection

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Quercetin regulates signaling pathways in neurodegenerative diseases, including NF‐κB, sirtuins, and PI3K/Akt. Studies show quercetin improves symptoms and pathology in neurodegenerative models. The study aims to incorporate laboratory research into practical medical treatment, focusing on quercetin's neuroprotective effects and optimal dosage ...
Md. Rezaul Islam   +13 more
wiley   +1 more source

Validating the Accuracy of Parkinson's Disease Clinical Diagnosis: A UK Brain Bank Case–Control Study

open access: yesAnnals of Neurology, EarlyView.
Objective Despite diagnostic criteria refinements, Parkinson's disease (PD) clinical diagnosis still suffers from a not satisfying accuracy, with the post‐mortem examination as the gold standard for diagnosis. Seminal clinicopathological series highlighted that a relevant number of patients alive‐diagnosed with idiopathic PD have an alternative post ...
Lazzaro di Biase   +2 more
wiley   +1 more source

Frequency and Early Predictors of Cognitive Deterioration in Amyotrophic Lateral Sclerosis: A Longitudinal Population‐Based Study

open access: yesAnnals of Neurology, EarlyView.
Objective The objective is to evaluate cognitive and behavioral progression and identify early predictors of these changes in a cohort of amyotrophic lateral sclerosis (ALS) patients. Methods A total of 161 ALS patients were tested at diagnosis (T0), and 107 were re‐tested after 1 year (T1) using cognitive/behavioral tests. All patients underwent whole‐
Barbara Iazzolino   +13 more
wiley   +1 more source

Sleep Disturbances and Pain Subtypes in Parkinson's Disease. [PDF]

open access: yesMedicina (Kaunas)
Diaconu S   +3 more
europepmc   +1 more source

Corrigendum to “Facial expression recognition in people with medicated and unmedicated Parkinson’s disease” [Neuropsychologia 41 (2003) 1047–1057]

open access: bronze, 2003
Reiner Sprengelmeyer   +7 more
openalex   +1 more source

Cyclic Alternating Pattern Dynamics in Individuals at Risk for Developing Parkinson's Disease

open access: yesAnnals of Neurology, EarlyView.
Objective The objective of this study was to investigate the differences in cyclic alternating patterns (CAP) metrics, a non‐rapid eye movement (NREM) sleep physiological rhythm, among recently diagnosed patients with Parkinson's disease (PD), and individuals at high and low risk for developing PD based on genetic and prodromal risk.
Andrew Dagay   +5 more
wiley   +1 more source

Blood DDIT4 and TRIM13 Transcript Levels Mark the Early Stages of Machado–Joseph Disease

open access: yesAnnals of Neurology, EarlyView.
Objective An abundance of select transcripts and proteins has been found to be dysregulated in blood samples of Machado–Joseph disease (MJD) carriers. Here, we aimed to: (1) identify blood transcriptional changes as potential biomarkers of MJD; (2) correlate levels of differentially expressed blood transcripts with MJD carriers features; and (3 ...
Ana F. Ferreira   +10 more
wiley   +1 more source

Dopamine Transporter Imaging as Objective Monitoring Biomarker in Parkinson's Disease

open access: yesAnnals of Neurology, EarlyView.
Objective Although dopamine transporter (DaT) imaging is a valuable diagnostic biomarker, few studies have investigated its utility in objectively monitoring disease progression in patients with Parkinson's disease (PD). To date, no study has established a longitudinal relationship between the DaT signal decline and the motor symptom increase ...
Verena Dzialas   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy